Printer Friendly

High-dose therapy plus BMT improve survival in follicular lymphoma patients.

High-dose radiochemotherapy (HDRC) with subsequent autologous bone marrow transplantation (ABMT) improves the estimated 10-year risk of death and relapse in follicular lymphoma patients in first complete or partial remission, according to the results of a phase II trial reported by researchers at Stanford (CA) University Medical Center.

At a median follow-up of 6.5 years, the estimated 10-year survival of 37 patients who underwent HCRC plus ABMT was 86% (97%, if lymphoma-related deaths were excluded). Two patients died of early transplant-related causes, 2 died of late acute leukemia, and 10 patients relapsed after transplantation. The estimated probability of death and relapse at 10 years was 14% and 30%, respectively, in the transplanted group-percentages that were considerably lower than the historical cohort of 188 similar patients. In addition, while survival in reference patients was adversely affected by high initial tumor burden and incomplete response to chemotherapy, it was not affected by these parameters in patients receiving HCRC plus ABMT. (Blood 2001;97:404-409.)
COPYRIGHT 2001 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:High-dose therapy plus BMT improve survival in follicular lymphoma patients.
Publication:Transplant News
Geographic Code:1USA
Date:Mar 16, 2001
Previous Article:Few infectious complications after BMT for breast cancer.
Next Article:Pretransplant disease severity influences success of liver transplant.

Related Articles
Preliminary data shows HDC+BMT combo therapy doesn't affect breast cancer survival rate; results questioned.
Children with bone marrow transplants often have lung problems, study finds.
Patients with high-risk blood, immune system cancers survive longer with stem cell transplants than BMTs.
HDC+BMT treatment option for breast cancer patients should continue to be evaluated, NCI researchers say.
Bone marrow transplant not helpful in high-risk pediatric ALL.
Allogeneic BMT may be best treatment for Hodgkin's lymphoma.
New methods for improving mismatched BMT success rates.
Patients in their 50 and 60s are good candidates for stem cell transplants after all, new studies show.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters